Actualités des traitements ARV: du Sud au Nord Pierre-Marie Girard IMEA & Hôpital ST Antoine DU IMEA FOURNIER PARIS VII Novembre 2009 Partie I

Les Cohortes au SUD

Castelnuovo B et al, CID, 2009

Second Line ARV in adults and children Renaud-Théry F, AIDS 2007

Cumulative proportion of patients needing 2 nd Line ARV Switch to 2d Line: mean 3% per year Renaud-Théry F, AIDS 2007

AIDS, 2009

Low performance of WHO criteria for the diagnosis of virological failure

CID, 2009

Smith AD et al, Lancet, 2009

Essais au SUD Essai DART « Big-Dart » REYADAK à Dakar« Small is beautiful » Essais PTME et Pédiatrie « Hit hard, hit early »

IAS July 2009 MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda TASO, Uganda University of Zimbabwe, Harare, Zimbabwe Joint Clinical Research Centre, Kampala, Uganda Infectious Diseases Institute, Makerere University, Uganda MRC Clinical Trials Unit, UK Imperial College, UK DFID, UK GlaxoSmithKline Gilead Sciences Boehringer-Ingelheim Abbott Rockefeller Foundation MRC, UK DART partners Support:

IAS July 2009 Survival Proportion alive Years from enrolment Entebbe Cohort (Uganda): pre-ART , median CD4 75 at enrolment: 57.7/100 PY DART LCM:2.2/100 PY CDM:2.9/100 PY

IAS July 2009 Resource allocation 6.7 million adults and children in Sub-Saharan Africa were estimated to need ART in December 2007 –only 2.2 million were receiving ART Global economic crisis is threatening programme funding Using DART to help resource allocation –what could be achieved in an ART programme with $1,000,000 over 5 years...

IAS July Number of patients LCM: TREAT 292CDM: TREAT 401 (extra 109) treated, alivetreated, died For $1,000,000 over 5 years Mean cost/patient: LCM $3,425, CDM $2,493 Assuming cost of patients not treated is $0. Based on difference in life-years from CEA.

IAS July 2009 Survival Proportion alive Years from enrolment Entebbe Cohort: pre-ART , median CD4 75 at enrolment: 57.7/100 PY DART LCM:2.2/100 PY CDM:2.9/100 PY

IAS July Number of patients LCM: TREAT 292CDM: TREAT 401 (extra 109) treated, alivetreated, died not treated, diednot treated, alive For $1,000,000 over 5 years Mean cost/patient: LCM $3,425, CDM $2,493 Total deaths 94 from Entebbe Cohort data Total deaths 35 Assuming cost of patients not treated is $0. Based on difference in life-years from CEA.

IAS July Number of patients LCM: TREAT 367CDM: TREAT 401 (extra 34) Excluding routine toxicity tests in LCM Mean cost/patient: LCM $2,726, CDM $2,493 Total deaths 49 treated, alivetreated, died not treated, diednot treated, alive from Entebbe Cohort data Total deaths 35 Assuming cost of patients not treated is $0. Based on difference in life-years from CEA.

Impact of « not-switching » on survival Risk of death Switching pts vs no Switching = 3.3 [ ]Ive P et al, CROI, 2009

Impact of « not-switching » on survival Risk of death Switching pts vs no Switching = 3.3 [ ]Ive P et al, CROI, 2009

Evaluation of didanosine/lamivudine and atazanavir QD first line regimen in HIV-1 infected adults in Senegal IMEA 031 trial BL Weeks % VL < 400 c/ml % VL < 50 c/ml % BL Weeks % VL < 400 c/ml % VL < 50 c/ml % BL Weeks % VL < 400 c/ml % VL < 50 c/ml % BL Weeks % VL < 400 c/ml % VL < 50 c/ml % BL Weeks % VL < 400 c/ml % VL < 50 c/ml %

Les Cohortes au Nord

Nature 2009 Hunt, JID 2009

Les Essais au Nord

Stratégies abandonnées Traitement tardif (< 200/mm3) Combinaisons initiales: En quadrithérapie IN+INN+IP En épargne de nucléosidiques par IP+INN ?? Traitements intermittents à cycles longs Interruptions programmées chez patients avec CD4 < 500/mm3 Initiation par nucléosidiques seuls Intensification simple (« Add on ») Immunothérapie non spécifique par IL2 Vaccinothérapie avec candidats-vaccins actuels

Premières lignes dARV

Première ligne: IP vs NNRTI

EFV vs LPV/r chez les patients naïfs à CD4+ < 200 : HIV-1 RNA <50 copies/mL à S Week Efavirenz (n = 95) LPV/RTV (n = 94) Nombre de Pts avec ARN VIH < 50 copies/mL EFV LPV % 53.2% HIV-1 RNA < 50 copies/mL (%) 79% 49% 64% 57% P = P = 0.15 EFV LPV/ RTV n = cell/mm 3 > 50 cell/mm 3 EFV supérieur à LPV/RTV: Δ 17% (CI 95%: 3.5% to 31.0%; P =.017) HIV-1 RNA < 50 copies/mL (%) Selon les CD4 à BL Madero JS, et al. IAC Abstract TUAB0104.

Patients naïfs: Etudes en cours ou prochaines avec molécules disponibles MERIT: CBV+EFV vs CBV+MVC COL11429: ABC/3TC + RAL APILOT-1:TDF/FTC+rATV vs rATV+MVC NEAT: TDF/FTC+rDRV vs RAL+rDRV CCTG589: rLPV+RAL vs Atripla ACTG A5262: rDRV+RAL Inv08: rLPV+RAL Merck072 RADAR: rDRV+RAL vs TDF/FTC+rDRV ANRS Optimal:Haart vs Haart + MVC chez pts CD4<200 A009: TDF/FTC + rLPV vs TDF/FTC+RAL M PROGRESS: TDF/FTC+ rLPV vs TDF/FTC+RAL GS001: TDF/FTC + rLPV vs TDF/FTC+RAL RAN: TDF/FTC + RAL vs TDF/FTC+rATV AI : TDF/FTC+rATV vs RAL+ATV bid ADARC 07-01: TDF/FTC+rATV ±RAL/MVC lors PI ANRS Optiprim: TDF/FTC+rDRV+RAL+MVC vs TDF/FTC+rDRV lors PI ClinicalTrials.gov